Eupraxia Pharmaceuticals EPRX Cash Flow Statement (2022-2026)

NASDAQ EPRX
$8.06 +0.43 (+5.64%)
At close: Nov 11, 2026 · 4:00 PM EST
Reported Financials

Eupraxia Pharmaceuticals Quarterly Cash Flow Statement

Periods 16 quarters
Latest Sep 2026

Eupraxia Pharmaceuticals reported cash from operations of -$0.01B and free cash flow of -$0.01B for the quarter ended Sep 2026, down 151.4% year over year. This cash flow statement covers 16 quarters of results from Dec 2022 through Sep 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow StatementCash Flow Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026 Sep2026
Operating Activities
Net Income -3.96M-9.51M-4.90M-10.61M-6.16M-6.06M-5.99M-7.53M-6.77M-8.75M-6.37M-16.72M-12.65M-14.49M-15.25M
Depreciation and DepletionDep. & Depletion 0.04M0.04M0.04M0.04M0.04M0.04M0.04M0.05M0.05M0.06M0.06M0.07M0.18M
Depreciation, Depletion & Amortization
Depreciation & Amortization (CF)Dep. & Amort. 0.04M0.04M0.04M0.04M0.04M0.04M0.04M0.05M0.05M0.06M0.06M0.07M0.18M
Share-based CompensationStock Comp. 0.32M0.43M0.36M0.31M0.21M1.47M0.51M1.03M1.49M1.12M0.45M5.70M2.25M3.03M2.13M
Cash from Discontinued OperationsCash from Discont. Ops -5.94M-10.19M
Gains from Sales and DivestituresGains Divest 138.000.00M-0.01M0.03M0.00M0.00M0.00M
Gains from Investment SecuritiesGains Investment 0.31M3.65M-1.88M-1.25M-0.77M-0.43M
Other non-cash itemsOther Non-Cash -0.02M0.02M0.00M-0.06M0.14M0.07M0.01M-0.07M-0.05M0.76M-0.33M1.19M-2.23M-2.24M0.29M
Change in Working Capital
Change in ReceivablesChange Receivables 0.00M0.04M-0.02M0.08M0.02M0.01M0.05M0.02M-0.01M0.11M-0.01M0.33M0.02M-0.03M0.50M
Change in Accrued ExpensesChange Accrued Exp. -1.47M1.17M0.23M0.65M0.11M1,865,706.65M-1,865,708.35M0.87M-0.89M0.34M1.15M1.76M1.54M1.35M1.77M
Change in Other Operating AssetsOther Assets Change 0.05M-0.24M0.07M0.24M0.13M-0.88M-0.07M1.78M0.20M-1.93M0.56M3.82M1.24M0.05M-0.87M
Change in Other Operating LiabilitiesOther Liabilities Change 0.00M0.00M0.00M0.00M0.00M0.00M0.00M0.00M0.00M867.000.00M0.00M0.01M
Other Working Capital ChangesOther WC Changes -0.05M0.24M-0.07M-0.24M-0.12M0.89M0.07M-1.78M-0.19M1.93M-0.55M-3.82M-1.23M-0.05M0.87M
Cash from OperationsCash from Ops. -4.57M-4.27M-5.94M-5.96M-6.14M-7.70M-10.19M-5.97M-6.00M-8.32M-4.51M-9.73M-10.15M-13.09M-11.33M
Investing Activities
Capital ExpendituresCapex -0.01M-0.01M-0.01M0.10M-0.01M-0.01M-0.04M0.16M-0.17M-0.17M-0.06M0.98M-0.33M-0.17M-0.13M
Sales of Property, Plant and EquipmentPP&E (Sale) 558.00
Change in Property, Plant and EquipmentChange in PP&E 0.01M0.01M0.01M-0.10M0.01M0.01M0.04M-0.16M0.17M0.17M0.06M-0.98M0.33M0.17M0.13M
Purchase of InvestmentsInvestments Purchased -79.72M
Other Investing Activities (as filed)Other investing (as filed) -0.01M-0.04M
Cash from Investing ActivitiesCash from Investing -0.01M-0.01M-0.01M-0.05M-0.01M0.02M-0.04M-0.04M-0.17M-0.17M-0.06M-0.19M-80.05M-0.17M29.94M
Financing Activities
Debt Issuance and Repayment
Long-Term Debt RepaymentsLT Debt Repayment -0.02M-0.02M-0.02M0.14M-0.02M-0.02M-0.02M9.20M
Net Long-Term Debt Issued (Repaid)Net LT Debt 0.02M0.02M0.02M-0.14M0.02M0.02M0.02M-9.20M
Net Debt Issuances and RepaymentsNet Debt Issuance 0.02M0.02M0.02M-0.14M0.02M0.02M0.02M-9.20M
Change in Capital Stock
Common Stock IssuedStock Issued 0.23M4.59M11.07M-10.61M22.85M-22.52M54.58M0.01M0.62M73.26M2.17M0.11M49.25M
Net Shares Issued and RepurchasedNet Shares Issued 0.23M4.59M11.07M-10.61M22.85M-22.52M54.58M0.01M0.62M73.26M2.17M0.11M49.25M
Net Equity Issued and RepurchasedNet Equity Issued 0.23M4.59M11.07M-10.61M22.85M-22.52M54.58M0.01M0.62M73.26M2.17M0.11M49.25M
Other financing activities (as filed) -0.02M-0.02M-0.02M-0.02M-0.02M-0.02M-0.02M-0.02M-0.02M-0.02M-0.02M-0.02M-0.04M-0.08M-0.10M
Cash from Financing ActivitiesCash from Financing 16.29M0.01M-4.60M31.73M
Additional items
Exchange Rate EffectFX Effect -0.19M0.79M0.18M-1.28M-0.45M
Change in Cash 10.33M-6.01M-14.83M25.71M
Ending Cash Balance 18.26M13.93M14.42M24.56M19.34M35.91M23.32M8.66M33.10M27.45M19.77M88.96M80.56M58.50M52.43M75.18M
Free Cash FlowFCF -4.56M-4.27M-5.93M-6.06M-6.13M-7.68M-10.15M-6.14M-5.83M-8.15M-4.45M-10.71M-9.82M-12.92M-11.19M
Net Cash FlowNCF -4.58M-4.28M10.33M-6.01M-6.14M-7.68M-14.83M25.71M-6.17M-8.48M-4.57M-9.92M-90.20M-13.27M18.61M

Eupraxia Pharmaceuticals Cash Flow Statement API

Pull Eupraxia Pharmaceuticals's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=EPRX&statement=CF&frequency=Quarter&period=all&api_key=YOUR_API_KEY